Crossmark

In HFREF patients, sacubitril/valsartan, given at relatively low doses, does not lead to increased mortality or hospitalization

Crossref DOI link: https://doi.org/10.1007/s00059-018-4690-6

Published Online: 2018-03-08

Published Print: 2019-11

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

De Vecchis, R.

Ariano, C.

Di Biase, G.

Noutsias, M.
License Information

Text and Data Mining valid from 2018-03-08
More Information

Article History

Received: 14 January 2018

Revised: 2 February 2018

Accepted: 3 February 2018

First Online: 8 March 2018

Compliance with ethical guidelines

:

: M. Noutsias has received grants by the Deutsche Forschungsgemeinschaft (DFG) through the Sonderforschungsbereich Transregio 19 “Inflammatory Cardiomyopathy” (SFB TR19; TP B2), and by the University Hospital Giessen and Marburg Foundation Grant “T cell functionality” (UKGM 10/2009). M. Noutsias has been consultant to the Institute for Cardiac Diagnosis and Therapy, Berlin (06/2004-06/2008) and has received honoraria for presentations and/or participated in advisory boards from AstraZeneca, Bayer, Boehringer Ingelheim, Fresenius, Miltenyi Biotech, Novartis, Pfizer and Zoll. R. De Vecchis, C. Ariano and G. Di Biase declare that they have no competing interests.

: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in the study.